This work is licensed under a Creative Commons Attribution 4.0 International License.
Combi-2
General Information
DRACP ID DRACP02035
Peptide Name Combi-2
Sequence FRWWHR
Sequence Length 6
UniProt ID Not available
PubChem CID Not available
Origin porcine cathelicidin peptide
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| Jurkat | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | Leukemia | IC50 ≥ 65 µM | MTT assay | 24h | 1 |
Hemolytic Activity RBC: IC50 ≥ 65 µM
Normal (non-cancerous) Cytotoxicity PBMC: IC50 ≥ 65 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C49H62N16O7
Absent amino acids ACDEGIKLMNPQSTVY
Common amino acids RW
Mass 107649
Pl 12.5
Basic residues 3
Acidic residues 0
Hydrophobic residues 3
Net charge 3
Boman Index -2686
Hydrophobicity -186.67
Aliphatic Index 0
Half Life
Mammalian: 1.1 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 11000
Absorbance 280nm 2200
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 32126228
Title Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin
Doi 10.1016/j.bbamem.2020.183228
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.